CONTINUUS Pharmaceuticals
CONTINUUS Pharmaceuticals specializes in end-to-end Integrated Continuous Manufacturing (ICM) for pharmaceuticals, providing innovative solutions for the manufacturing of small molecule drugs.
Integrated Continuous Manufacturing (ICM) Solutions
CONTINUUS Pharmaceuticals specializes in providing end-to-end Integrated Continuous Manufacturing (ICM) solutions for the pharmaceutical industry. The company's ICM platform, initially developed through a $65 million joint research project between Novartis and MIT, offers a breakthrough approach to the manufacturing of small molecule drugs. ICM processes are fully automated and can be re-configured in a 'plug-and-play' fashion to produce various compounds. This innovative technology reduces manufacturing lead times from months to days, significantly lowering costs and improving the affordability and accessibility of pharmaceuticals globally.
Continuous Technologies for Pharmaceutical Manufacturing
CONTINUUS Pharmaceuticals has developed proprietary continuous technologies that provide distinct advantages over conventional batch technologies. These include a continuous rotary filtration system for API separation and purification, a continuous solvent recovery system reducing solvent usage and waste, and an automated continuous clarification bypass system for removing suspended particulate matter. The company also explores continuous manufacturing of injection molding tablets via Extrusion-Molding-Coating (EMC) through feasibility studies, showcasing its capability to innovate across various pharmaceutical manufacturing processes.
Collaborations in the Pharmaceutical Sector
CONTINUUS Pharmaceuticals collaborates with government agencies and leading global companies in the pharmaceutical sector. These collaborations enable the development and implementation of their Integrated Continuous Manufacturing (ICM) solutions on a broader scale. By working closely with industry leaders, CONTINUUS ensures that its continuous manufacturing technologies can meet rigorous pharmaceutical standards and contribute to more efficient and sustainable drug production processes.
Environmental and Economic Benefits of ICM
The Integrated Continuous Manufacturing (ICM) processes developed by CONTINUUS Pharmaceuticals offer significant environmental and economic benefits. These continuous flow processes are designed to produce high-quality drugs with better quality assurance and reduced costs, with potential savings ranging from 30% to over 50%. The environmentally friendly technologies result in higher yields, lower solvent requirements, and efficient solvent recovery systems, thereby reducing waste and improving sustainability in pharmaceutical manufacturing.
Pilot Plant and Feasibility Studies
CONTINUUS Pharmaceuticals operates a pilot plant dedicated to end-to-end Integrated Continuous Manufacturing (ICM) of pharmaceuticals. This facility allows the company to conduct feasibility studies and demonstrate the practical applications of their continuous manufacturing technologies. By evaluating the continuous manufacturing of injection molding tablets via Extrusion-Molding-Coating (EMC) and other processes, CONTINUUS continually advances its capabilities and showcases the potential for transforming traditional pharmaceutical manufacturing methods.